CN113906010A - 治疗患有非小细胞肺癌的女性非吸烟者的方法 - Google Patents

治疗患有非小细胞肺癌的女性非吸烟者的方法 Download PDF

Info

Publication number
CN113906010A
CN113906010A CN202080034238.XA CN202080034238A CN113906010A CN 113906010 A CN113906010 A CN 113906010A CN 202080034238 A CN202080034238 A CN 202080034238A CN 113906010 A CN113906010 A CN 113906010A
Authority
CN
China
Prior art keywords
lung cancer
small cell
cell lung
patient
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034238.XA
Other languages
English (en)
Chinese (zh)
Inventor
阿迪亚·库尔卡米
阿伦·阿塞坦比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanteng Pharmaceutical Co
Original Assignee
Lanteng Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanteng Pharmaceutical Co filed Critical Lanteng Pharmaceutical Co
Priority to CN202510278250.XA priority Critical patent/CN120078760A/zh
Publication of CN113906010A publication Critical patent/CN113906010A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CN202080034238.XA 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法 Pending CN113906010A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510278250.XA CN120078760A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815762P 2019-03-08 2019-03-08
US62/815,762 2019-03-08
PCT/US2020/021615 WO2020185640A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510278250.XA Division CN120078760A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Publications (1)

Publication Number Publication Date
CN113906010A true CN113906010A (zh) 2022-01-07

Family

ID=72427123

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080034238.XA Pending CN113906010A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法
CN202510278250.XA Pending CN120078760A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510278250.XA Pending CN120078760A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Country Status (11)

Country Link
US (1) US20220168258A1 (https=)
EP (1) EP3935043A4 (https=)
JP (2) JP2022525040A (https=)
KR (1) KR20220047208A (https=)
CN (2) CN113906010A (https=)
AU (2) AU2020235823A1 (https=)
BR (1) BR112021017716A2 (https=)
CA (1) CA3132827A1 (https=)
MX (1) MX2021010745A (https=)
SG (1) SG11202109705YA (https=)
WO (1) WO2020185640A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014891A (zh) * 2008-03-14 2011-04-13 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008352597B2 (en) * 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014891A (zh) * 2008-03-14 2011-04-13 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NORIYUKI MASUDA等: ""Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer"", 《CANCER CHEMOTHER PHARMACOL》 *
杜海洲等: "非小细胞肺癌靶向药物的开发研究进展", 《中国新药杂志》 *

Also Published As

Publication number Publication date
JP2022525040A (ja) 2022-05-11
EP3935043A4 (en) 2023-01-11
JP2025081338A (ja) 2025-05-27
BR112021017716A2 (pt) 2021-11-16
MX2021010745A (es) 2021-12-15
US20220168258A1 (en) 2022-06-02
EP3935043A1 (en) 2022-01-12
AU2020235823A1 (en) 2021-11-04
WO2020185640A1 (en) 2020-09-17
AU2025267367A1 (en) 2025-12-04
KR20220047208A (ko) 2022-04-15
CN120078760A (zh) 2025-06-03
SG11202109705YA (en) 2021-10-28
CA3132827A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
Monnet et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
US10933061B2 (en) Pyrvinium pamoate therapies and methods of use
JP2009102408A (ja) ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療
TW201717933A (zh) 使用包含微脂伊立替康（ｉｒｉｎｏｔｅｃａｎ）及奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）之組合療法治療轉移性胰臟癌的方法
Wozniacka et al. Optimal use of antimalarials in treating cutaneous lupus erythematosus
Sonavane et al. Topical curcumin‐based cream is equivalent to dietary curcumin in a skin cancer model
WO2020234454A1 (en) Combination treatment of cancer targeting energy metabolism and intracellular ph
US11491168B2 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
US9155761B2 (en) Method for the treatment of cancer
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
CN113906010A (zh) 治疗患有非小细胞肺癌的女性非吸烟者的方法
AU2020248270A1 (en) Chiauranib for treatment of small cell lung cancer
JP2020512408A (ja) 肺がんの治療に使用するための組み合わせ
KR20120104594A (ko) 췌장암의 치료 방법
WO2025232723A1 (en) Treatment method with focal adhesion kinase inhibitor
US20260000740A1 (en) Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
KR20200104160A (ko) 폐암 치료 또는 예방용 약학 조성물
TW202532061A (zh) 治療非小細胞肺癌(NSCLC)的地美司納(Dimesna)及培美曲塞(Pemetrexed)之組合
US9801840B1 (en) Pharmaceutical composition and use thereof
JP2013510126A (ja) コリン含有医薬組成物
de Weger et al. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
US20120309845A1 (en) Dosing regimens and methods for treating or preventing acute myeloid leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination